The pleiotropic actions of vitamin D

BioEssays

Volumn 26, Issue 1, 2004, Pages 21-28

  Lin, Roberto ^a   White, John H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; CALCITRIOL RECEPTOR; CALCIUM; COMPLEMENTARY DNA; LIGAND; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; SEOCALCITOL; STEROID; TRANSCRIPTION FACTOR; VITAMIN D; VITAMIN D RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL; ANIMAL CELL; ANIMAL MODEL; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; BREAST CANCER; CALCIUM HOMEOSTASIS; CANCER PREVENTION; CANCER THERAPY; CELL DIFFERENTIATION; CELL DIVISION; CENTRAL NERVOUS SYSTEM; CHEMICAL MODEL; COLON CANCER; CRYSTAL STRUCTURE; DNA BINDING; DNA REPAIR; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; GENETICS; HEAD AND NECK CANCER; HUMAN; IMMUNOMODULATION; LIGAND BINDING; METABOLISM; MOLECULAR CLONING; MOUSE; NEOPLASM; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; PHYSIOLOGY; PROSTATE CANCER; PROTEIN TERTIARY STRUCTURE; PSORIASIS; RAT; REVIEW; STROKE; VITAMIN D RESPONSIVE ELEMENT; X RAY CRYSTALLOGRAPHY;

ANIMALS; CALCITRIOL; CALCIUM; CELL DIFFERENTIATION; CELL DIVISION; CENTRAL NERVOUS SYSTEM; CLONING, MOLECULAR; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CALCITRIOL; TRANSCRIPTION, GENETIC; VITAMIN D;

EID: 0345743611     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10368     Document Type: Review

References (85)

1. Unraveling the enigma of vitamin D. Beyond Discovery, National Academy of Sciences, USA. www.beyonddiscovery.org/Includes/ DBLink.asp?ID = 1176.
2. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiological Rev 1998;78:1193-1231.
3. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed J Bone Min Res 1998;13:325-349.
4. Okuda K, Usui E, Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J Lipid Res 1995;36:1641-1652.
5. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988;85:3294-3298.
6. Chawla A, Repa J, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: Opening the X-files Science 2001;294:1866-1870.
7. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465-474.
8. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D-3 receptor: a network of coactivator interactions. Gene 2000;246:9-21
9. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 1:1269-1304.
10. 3 response elements formed by inverted palindromes: Polarity-directed ligand sensitivity of VDR-RXR heterodimer-mediated transactivation. Mol Cell Biol 1995;15:1154-1161.
11. Thummel KE, Brimer C, Yasuda K, Thottassery, J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J, Schuetz E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 2001;60:1399-1406.
12. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 2002;277:25125-25132.
13. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. BioChem Biophys Res Comm 2002;299:730-738.
14. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000;5:173-179.
15. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocrine Rev 1999;20:156-188.
16. Gardezi SA, Nyugen C, Malloy PJ, Posner GH, Feldman D, Peleg S. A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem 2001;276:29148-29156.
17. Swann SL, Bergh J, Farach-Carson MC, Ocasio CA, Koh JT. Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J Am Chem Soc 2002;124:13795-13805.
18. Kittaka A, Kurihara M, Peleg S, Suhara Y, Takayama H. 2 alpha-(3-hydroxypropyl)- and 2 alpha-(3-hydroxypropoxy)-1 alpha,25-dihydroxyvitamin D-3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets. Chem Pharmacol Bull 2003;51:357-358.
19. Peterson BR. Augmenting vitamin D to combat genetic disease. Chem Biol 2002;9:1265-1266.
20. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 2001;8:1679-1697.
21. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 2001;41:421-442
22. Zitterman A. Vitamin D in preventive medicine: are we ignoring the evidence? Brit J Nutrition 2003;89:552-572
23. Lipkin M, Newmark H, Boone CW, Kelloff GJ. Calcium, vitamin D, colon cancer. Cancer Res 1991;51:3069-3070.
24. 3 of hamster cheek pouch carcinoma induced with 9,10-dimethyl-1,2-benzanthracene with a discussion of the role of intracellular calcium in the development of tumors. Pathol MicroBiol (Basel) 1973;39:446-460.
25. 3 on N-methyl-N′-nitro-N-nitrosoguanidine-induced gastrointestinal carcinogenesis in Wistar rats. Cancer Lett 1998;122:227-230.
26. Wood AW, Chang RL, Huang M-T, Uskokovic M, Conney AH. 1α,25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. BioChem Biophys Res Comm 1983;116:605-611.
27. 3. Cancer Res 1985;45:5426-5430
28. Sahpazidou D, Stravoravdi P, Toliou T, Geromichalos G, Zafiriou G, Natsis K, Gigis P. Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1089, a vitamin D analogue. Oncol Res 2003;13:261-268.
29. 3: Implications of cell growth and signaling. Endocrine Rev 2002;23:763-786.
30. Colston K, Mackay AG, James AY, Binderup L. EB1089: a new vitamin D3 analog that inhibits the growth of breast cancer cells in vivo and in vitro. BioChem Pharmacol 1992;44:2273-2280.
31. Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89:182-185.
32. Zhuang S-H, Bernstein KL. Antiproliferative effect of 1α, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinol 1998;139:1197-1207.
33. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-2649.
34. 3 and its Analog EB1089 under Growth Inhibitory Conditions in Squamous Carcinoma Cells. Mol Endocrinol 2001;15:1127-1139.
35. Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, Nishii Y, DeLuca HF, Suda T. 1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983;80:201-204.
36. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987;47:21-25.
37. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog EB1089. Endocrinol 1998;139:2102-2110.
38. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779-782.
39. Prudencio J, Akutsu N, Wong T, Bastien Y, Lin R, Black MJ, Alaoui-Jamali M, White JH. Action of low calcemic 1,25-dihydroxyvitamin D3 analog EB1089 in head and neck squamous cell carcinoma. J Nat Cancer Inst 2001;93:745-753.
40. Hansen CM, Hamberg KJ, Binderup E, Binderup L. Seocalcitol (EB1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharmaceutic Design 2000;6:803-828.
41. Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-153.
42. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation and induction of WAF1 WAF1 in myeloid leukemia. Blood 1996;88:2201-2209.
43. KIP1 in vitamin D analogue-treated cancer cells. Endocrinol 2003;144:749-753
44. Kudo Y, Kitaiima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-Phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001;61:7044-7047.
45. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Nat Acad Sci USA 2001;98:5043-5048.
46. Hosomi J, Hosol J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of mouse epidermal cells by 1α,25-dihydroxyvitamin D3. Endocrinol 1983;113:1950-1957.
47. Dace A, Martin-el Yadizi C, Bonne J, Planells R, Torresani J. Calcitriol is a positive effector of adipose differentiation in the OB17 cell line: relationship with the adipogenic action of triiodothyronine. Biochem Biophys Res Comm 1997;232:771-776.
48. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson T, White JH. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 signaling on cell proliferation, differentiation and immune system regulation. Mol Endocrinol 2002;16:1243-1256.
49. Islam S, Carey TE, Wolf GT, Wheelock MJ, Johnson KR. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol 1996;135:1643-1654.
50. Tomita K, van Bokhoven A, van Leenders GJLH, Ruijter ETG, Jansen CFJ, Bussmakers MJG, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60:3650-3654.
51. Galbiati F, Polastri L, Thorens B, Dupraz P, Fiorina P, Cavallaro U, Christofori G, Davalli AM. Molecular pathways involved in the anti-neoplastic effects of calcitriol on insulinoma cells. Endocrinol 2003;144:1832-1841.
52. Hollander MC, et al. Genomic instability in Gadd45α-deficient mice. Nature Genet 1999;23:176-184.
53. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell BioChem 2003;88:363-371
54. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Breast Cancer Cells: Gene Expression Patterns Assessed by cDNA Microarray. Breast Cancer Res & Treatment 2003;80:49-62.
55. Danilenko M, Wang Q, Wang XN, Levy J, Sharoni Y, Studzinski GP. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1 alpha 25-dihydroxyvitamin D-3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003;63:1325-1332.
56. Petersen AB, Gniadecki R, Vicanova J, Thorn T, Wulf HC. Hydrogen peroxide is responsible for UVA-induced DNA damage measured by alkaline comet assay in HaCaT keratinocytes. J PhotoChem PhotoBiol 2000;59:123-131
57. Lee J, Youn JI. The photoprotective effect of 1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J Dermatol Sci 1998;18:11-18.
58. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Nat Acad Sci 2001;98:3410-3415.
59. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1, 25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221:1181-1183.
60. Brennan A, Katz DR, Nunn JD, Barker S, Hewison M, Fraher LJ, O'Riordan JL. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987;61:457-461.
61. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984;133:1748-1754.
62. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Internat Immunopharmacol 2002;2:1017-1028.
63. Mathieu C, van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R. In vitro and in vivo analysis of the immune system of vitamin D receptor-knock out mice. J Bone Miner Res 2001;16:2057-2065.
64. O'Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002;109:1091-1099.
65. Panda DK. Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 2001;98:7498-7503
66. Penna G, Adorini L. 1,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-2411.
67. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1,25-dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Nat Acad Sci USA 2001;98:680-705
68. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001;145:351-357.
69. Alroy I, Towers T, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995;15:5789-5799.
70. Takeuchi A, Reddy G, Kobayashi T, Okano T, Park J, Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1,25-dihydroxyvitamin D3-mediated effects. J Immunol 1998;160:209-218.
71. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrine Rev 2000;21:457-487.
72. Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, Giannetti A, Girolomoni G, Pastore S. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:871-877.
73. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie ANJ. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000;191:1069-1075.
74. Lemire JM, Archer DC. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
75. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing enoephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996:93:7861-7864.
76. Bourke JF, Iqbal SJ, Hutchinson PE. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 micrograms/g) and calcipotriol (50 micrograms/g) in the treatment of chronic plaque psoriasis vulgaris. Acta Derm-Venereol 1997;77:228-230
77. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Brit J Dermatol. 1997;137:581-586.
78. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Brit Med J 2000;320:963-967.
79. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Brit J Dermatol 2002;146:351-364.
80. Prufer K, Veenstra TD, Jirikowski GF, Kumar R. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat 1999;16:135-145.
81. Kumar R. 1α,25-dihydroxyvitamin D3-not just a calciotropic hormone. Nephron 2002;91:576-581.
82. 3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging 1998;19:469-477.
83. Wang Y, Ciang YH, Su TP, Hayashi T, Morales M, Hoffer BJ, Lin SZ. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000;39:873-880.
84. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with down-regulation of L-type calcium channel expression in hippocampal neurons. J NeuroSci 2001;21:98-108.
85. Shinpo K, Kikuchi S, Sasaki H, Moriwaka F, Tashiro K. Effect of 1,25-dihydroxyvitamin D-3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J NeuroSci Res 2000;62:374-382.